Home Microbiology HCV

HCV Inhibitors

HCV Products

  • All (9)
  • HCV Inhibitors (9)
  • New HCV Products
Cat.No. Product Name Information Product Use Citations Product Validations
S2728 AG-1478 AG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. This compound inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).
Cell Death Dis, 2025, 16(1):479
J Stroke Cerebrovasc Dis, 2025, 34(6):108315
Biomed Pharmacother, 2024, 180:117523
Verified customer review of AG-1478
S1848 Curcumin Curcumin (Diferuloylmethane, Natural Yellow 3, Turmeric yellow) is the principal curcuminoid of the popular Indian spice turmeric, which is a member of the ginger family (Zingiberaceae). It is an inhibitor of p300 histone acetylatransferase（IC50~25 μM）and Histone deacetylase (HDAC); activates Nrf2 pathway and supresses the activation of NF-κB. This compound induces mitophagy, autophagy, apoptosis, and cell cycle arrest with antitumor activity. It reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. This chemical exhibits anti-infective properties against various human pathogens like the influenza virus, hepatitis C virus, HIV and so on.
J Biol Chem, 2025, 301(7):110305
Mol Pain, 2025, 21:17448069251323668
Cancer Cell Int, 2024, 24(1):303
Verified customer review of Curcumin
S2310 Honokiol Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. This compound causes G0/G1 phase arrest, induces apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway. It inhibits hepatitis C virus (HCV) infection. Phase 3.
J Adv Res, 2025, S2090-1232(25)00062-1
J Nanobiotechnology, 2025, 23(1):414
Oncol Lett, 2025, 29(4):191
Verified customer review of Honokiol
S8133 Resiquimod (R-848) Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2.
Nature, 2025, 644(8078):1058-1068
J Virol, 2025, e0128025.
Int J Nanomedicine, 2024, 19:3589-3605
S1384 Mizoribine Mizoribine is an imidazole nucleoside and an immunosuppressant that inhibits HCV RNA replication with IC50 of ~ 100 μM for anti-HCV activity. This compound is a selective inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthetase. It also inhibits SARS-CoV.
EMBO J, 2023, e110620.
ProQuest, 2023,
The Faculty of the Graduate School of Arts and Sciences Brandeis University, 2023,
S6689 Merimepodib Merimepodib (Merimempodib, MMPD, VI-21,497, VX-497) is a potent, specific, and reversible inosine monophosphate dehydrogenase(IMPDH) inhibitor with antiviral activity against hepatitis C virus (HCV) and a variety of DNA and RNA viruses in vitro. This compound is an immunosuppressive agent.
Cancer Cell, 2022, 40(9):957-972.e10
Cancer Cell, 2022, 40(9):957-972.e10
S0349 Inarigivir soproxil Inarigivir soproxil (GS 9992, SB 9200) is an oral agonist of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. This compound has broad-spectrum antiviral activity against RNA viruses with EC50 of 2.2 μM and 1.0 μM for HCV 1a and HCV 1b.
Transl Oncol, 2025, 51:102230
E6581New Mipomersen Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B-100 (apoB-100) that causes selective degradation of apoB-100 mRNA, thereby inhibiting protein translation. This leads to reductions in low-density lipoprotein cholesterol (LDL-C) and other apoB-containing lipoprotein levels. Mipomersen is used as an adjunct treatment for homozygous familial hypercholesterolemia (FH).
S4434 Ledipasvir acetone Ledipasvir (GS-5885) acetone is the active ingredient of Ledipasvir. Ledipasvir is a potent, oral active inhibitor of the hepatitis C virus (HCV) NS5A with EC50 of 31 pM and 4 pM against GT1a and GT1b replicon, respectively.
S2728 AG-1478 AG-1478 is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. This compound inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).
Cell Death Dis, 2025, 16(1):479
J Stroke Cerebrovasc Dis, 2025, 34(6):108315
Biomed Pharmacother, 2024, 180:117523
 Verified customer review of AG-1478
S1848 Curcumin Curcumin (Diferuloylmethane, Natural Yellow 3, Turmeric yellow) is the principal curcuminoid of the popular Indian spice turmeric, which is a member of the ginger family (Zingiberaceae). It is an inhibitor of p300 histone acetylatransferase（IC50~25 μM）and Histone deacetylase (HDAC); activates Nrf2 pathway and supresses the activation of NF-κB. This compound induces mitophagy, autophagy, apoptosis, and cell cycle arrest with antitumor activity. It reduces renal damage associated with rhabdomyolysis by decreasing ferroptosis-mediated cell death. This chemical exhibits anti-infective properties against various human pathogens like the influenza virus, hepatitis C virus, HIV and so on.
J Biol Chem, 2025, 301(7):110305
Mol Pain, 2025, 21:17448069251323668
Cancer Cell Int, 2024, 24(1):303
 Verified customer review of Curcumin
S2310 Honokiol Honokiol is the active principle of magnolia extract that inhibits Akt-phosphorylation and promotes ERK1/2 phosphorylation. This compound causes G0/G1 phase arrest, induces apoptosis, and autophagy via the ROS/ERK1/2 signaling pathway. It inhibits hepatitis C virus (HCV) infection. Phase 3.
J Adv Res, 2025, S2090-1232(25)00062-1
J Nanobiotechnology, 2025, 23(1):414
Oncol Lett, 2025, 29(4):191
 Verified customer review of Honokiol
S8133 Resiquimod (R-848) Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2.
Nature, 2025, 644(8078):1058-1068
J Virol, 2025, e0128025.
Int J Nanomedicine, 2024, 19:3589-3605
S1384 Mizoribine Mizoribine is an imidazole nucleoside and an immunosuppressant that inhibits HCV RNA replication with IC50 of ~ 100 μM for anti-HCV activity. This compound is a selective inhibitor of inosine-5'-monophosphate dehydrogenase (IMPDH) and guanosine monophosphate synthetase. It also inhibits SARS-CoV.
EMBO J, 2023, e110620.
ProQuest, 2023,
The Faculty of the Graduate School of Arts and Sciences Brandeis University, 2023,
S6689 Merimepodib Merimepodib (Merimempodib, MMPD, VI-21,497, VX-497) is a potent, specific, and reversible inosine monophosphate dehydrogenase(IMPDH) inhibitor with antiviral activity against hepatitis C virus (HCV) and a variety of DNA and RNA viruses in vitro. This compound is an immunosuppressive agent.
Cancer Cell, 2022, 40(9):957-972.e10
Cancer Cell, 2022, 40(9):957-972.e10
S0349 Inarigivir soproxil Inarigivir soproxil (GS 9992, SB 9200) is an oral agonist of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. This compound has broad-spectrum antiviral activity against RNA viruses with EC50 of 2.2 μM and 1.0 μM for HCV 1a and HCV 1b.
Transl Oncol, 2025, 51:102230
E6581New Mipomersen Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B-100 (apoB-100) that causes selective degradation of apoB-100 mRNA, thereby inhibiting protein translation. This leads to reductions in low-density lipoprotein cholesterol (LDL-C) and other apoB-containing lipoprotein levels. Mipomersen is used as an adjunct treatment for homozygous familial hypercholesterolemia (FH).
S4434 Ledipasvir acetone Ledipasvir (GS-5885) acetone is the active ingredient of Ledipasvir. Ledipasvir is a potent, oral active inhibitor of the hepatitis C virus (HCV) NS5A with EC50 of 31 pM and 4 pM against GT1a and GT1b replicon, respectively.
E6581New Mipomersen Mipomersen (ISIS 301012 free base) is an antisense oligonucleotide inhibitor of apolipoprotein B-100 (apoB-100) that causes selective degradation of apoB-100 mRNA, thereby inhibiting protein translation. This leads to reductions in low-density lipoprotein cholesterol (LDL-C) and other apoB-containing lipoprotein levels. Mipomersen is used as an adjunct treatment for homozygous familial hypercholesterolemia (FH).